vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.…
VTv Therapeutics: Q3 Earnings Snapshot
vTv Therapeutics (NASDAQ: VTVT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 26 employees.
The shares were at 15.51 USD on 20 November 2026, down 39.1% over 52 weeks. Its 52-week range is 15.47 USD to 44.00 USD, and it trades at the bottom of that range.
Its market capitalisation is 62.22M USD.
vTv Therapeutics reports return on equity of -41.9% and an operating margin of -29.8%.
It holds more cash than debt, a net cash position of 77.16M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 56.00 USD is 261.1% above the current price. The next earnings report is expected on 18 March 2027.